MX2015008225A - Composicion de cabazitaxel. - Google Patents

Composicion de cabazitaxel.

Info

Publication number
MX2015008225A
MX2015008225A MX2015008225A MX2015008225A MX2015008225A MX 2015008225 A MX2015008225 A MX 2015008225A MX 2015008225 A MX2015008225 A MX 2015008225A MX 2015008225 A MX2015008225 A MX 2015008225A MX 2015008225 A MX2015008225 A MX 2015008225A
Authority
MX
Mexico
Prior art keywords
composition
cabazitaxel
cyclodextrin
sulfobutylether beta
sulfobutylether
Prior art date
Application number
MX2015008225A
Other languages
English (en)
Other versions
MX371067B (es
Inventor
Valery Alakhov
Grzegorz Pietrzynski
Kishore Patel
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Publication of MX2015008225A publication Critical patent/MX2015008225A/es
Publication of MX371067B publication Critical patent/MX371067B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con una composición que comprende: (a) cabazitaxel, y (b) sulfobutiléter beta ciclodextrina. Esta composición presenta estabilidad inesperadamente deseable en medios acuosos, lo que permite que se administren dosificaciones terapéuticas del fármaco sin el uso de ya sea etanol o tensioactivos.
MX2015008225A 2012-12-24 2013-12-23 Composicion de cabazitaxel. MX371067B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261848172P 2012-12-24 2012-12-24
PCT/IB2013/003255 WO2014122498A2 (en) 2012-12-24 2013-12-23 Cabazitaxel composition

Publications (2)

Publication Number Publication Date
MX2015008225A true MX2015008225A (es) 2016-07-20
MX371067B MX371067B (es) 2020-01-15

Family

ID=51300216

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008225A MX371067B (es) 2012-12-24 2013-12-23 Composicion de cabazitaxel.

Country Status (16)

Country Link
US (1) US9919053B2 (es)
EP (1) EP2934593B1 (es)
JP (1) JP6498610B2 (es)
KR (1) KR102161866B1 (es)
CN (1) CN105142671B (es)
AU (1) AU2013377404B2 (es)
BR (1) BR112015015202B8 (es)
CA (1) CA2900508C (es)
DK (1) DK2934593T3 (es)
ES (1) ES2771423T3 (es)
HU (1) HUE048505T2 (es)
MX (1) MX371067B (es)
PL (1) PL2934593T3 (es)
PT (1) PT2934593T (es)
RU (1) RU2678772C2 (es)
WO (1) WO2014122498A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109731A1 (en) * 2016-12-16 2018-06-21 Orbicular Pharmaceutical Technologies Private Limited Pharmaceutical compositions of taxane and its derivatives
CN113559277B (zh) * 2018-01-11 2023-11-17 比卡生物科技（广州）有限公司 一种注射用卡巴他赛组合物及其制备方法
JP7274785B2 (ja) * 2018-07-25 2023-05-17 ビカ バイオテクノロジー （グアンジョウ） カンパニー リミテッド 注射用ドセタキセル組成物およびそのための調製法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233945A1 (en) * 2003-07-18 2005-10-20 Larry Brown Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation
EP1443969A2 (en) * 2001-10-18 2004-08-11 Decode Genetics EHF Non-inclusion cyclodextrin complexes
JP2005022989A (ja) * 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
AU2004285032A1 (en) * 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel

Also Published As

Publication number Publication date
KR20150127035A (ko) 2015-11-16
RU2015130495A (ru) 2017-01-27
US9919053B2 (en) 2018-03-20
WO2014122498A3 (en) 2014-12-04
PT2934593T (pt) 2020-03-09
CN105142671B (zh) 2018-09-14
US20150328321A1 (en) 2015-11-19
CA2900508C (en) 2021-04-13
RU2678772C2 (ru) 2019-02-01
ES2771423T3 (es) 2020-07-06
HUE048505T2 (hu) 2020-07-28
JP2016508138A (ja) 2016-03-17
JP6498610B2 (ja) 2019-04-10
CA2900508A1 (en) 2014-08-14
WO2014122498A2 (en) 2014-08-14
CN105142671A (zh) 2015-12-09
MX371067B (es) 2020-01-15
AU2013377404B2 (en) 2018-08-23
EP2934593A4 (en) 2016-08-10
PL2934593T3 (pl) 2020-05-18
EP2934593A2 (en) 2015-10-28
DK2934593T3 (da) 2020-02-17
AU2013377404A2 (en) 2015-08-27
KR102161866B1 (ko) 2020-10-05
BR112015015202B1 (pt) 2021-12-21
EP2934593B1 (en) 2020-02-05
BR112015015202A2 (pt) 2017-07-11
AU2013377404A1 (en) 2015-07-30
BR112015015202B8 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
GB2484244A (en) Anaesthetic formulation
AR127861A2 (es) Composición farmacéutica que comprende inhibidores del proteasoma peptídico y ciclodextrina
BR112014018110A8 (pt) Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2014194195A3 (en) Cyclodextrin-based polymers for the therapeutic delivery
NZ745556A (en) Androgen receptor modulator and uses thereof
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
MX2015009773A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
RS52633B (en) CANCER TREATMENT FORMULATION
SG171542A1 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
BR122019021714B8 (pt) preparação compreendendo vitamina b12 e butanol e butafosfano, e seu uso
BR112015006605A2 (pt) vacina atenuada viva, método de produzir um arterivírus, arterivírus, e, complexo plp2-ubiquitina ou complexo plp2-isg15
MX2013006644A (es) Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.
MX2015017273A (es) Composiciones que comprenden acido hialuronico reticulado y ciclodextrina.
UA99979C2 (uk) Комплекси включення піноцембрину з циклодекстрином або його похідними
MX2012014479A (es) Formulaciones que incluyen amiodarona y sales de la misma y metodos para su fabricacion y uso.
MX2021015846A (es) Derivados de antraciclina.
MX2015008225A (es) Composicion de cabazitaxel.
BR112016000092A2 (pt) nanopartículas lipídicas para a cicatrização de feridas
MX2016015208A (es) Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SOFTKEMO PHARMA CORP.

FG Grant or registration